NCT01088880

Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 12 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Establish the safety and efficacy of 3 months treatment with canakinumab in patients with colchicine resistant Familial Mediterranean Fever.

Conditions

• Familial Mediterranean Fever

Interventions

Type	Name	Description
DRUG	Canakinumab

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2010-03-17
• Last updated: 2012-05-01

Locations

1 site across 1 country: Turkey (Türkiye)